Mindfulness based program for newly diagnosed Parkinson’s patients.
Objective: To investigate the impact of 8-week course of Mindfulness based intervention program on motor and or non-motor symptoms of PD assessed by improvement in…Optimizing patient-centric clinical outcome assessments for use in Parkinson’s disease clinical trials: Critical Path for Parkinson’s multistakeholder initiative
Objective: To advance patient-centric endpoints for use in early-stage Parkinson’s disease (PD) clinical trials. Background: Limitations with currently available patient-centric clinical outcome assessments (COAs) has…Milder presentation in two compound heterozygote cases of spastic paraplegias type 5
Objective: Describing two mild compound heterozygote SPG5A cases. Background: Hereditary spastic paraplegia type 5 (SPG5A) is an autosomal recessive neurodegenerative disease caused by variants in…Factors related to the antidepressant effect of safinamide in Parkinson’s disease. A post-hoc analysis of SADNESS-PD study
Objective: To assess the role of different factors in the antidepressant effect of safinamide in Parkinson’s disease (PD) Background: SADNESS-PD was a real-life, multicenter, retrospective…Apathy and Volume of Tissue Activated (VTA) following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Cohort
Objective: To determine frequency and/or predictors of improvement or worsening of apathy, we evaluated this behavior among those who received bilateral subthalamic deep brain stimulation…Metabolic Biomarkers of Parkinson’s Disease in Peripheral Tissue
Objective: The goal of this study was to use magnetic resonance spectroscopy (MRS) to test whether muscles of individuals with Parkinson’s disease (PD) possess a…Differences between two cognitive assessment instruments used in Parkinson’s disease in Kyrgyzstan
Objective: The aim of this study was to determine differences between Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in PD patients from Kyrgyzstan.…Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey
Objective: To understand the perceptions and knowledge that people with Parkinson’s disease (PD) have about their treatment, available options for advanced PD, and to determine…Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa
Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 153
- Next Page »